Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Thyrocare Technologies - Pricing in the growth uptick - ICICI Securities

Posted On: 2020-10-30 08:23:48


Thyrocare Technologies' (Thyrocare) reported healthy Q2FY21 results supported by strong growth in COVID-19 tests and recovery in non-COVID tests. Consolidated revenue grew 31.8% YoY to Rs1.5bn (I-Sec: Rs1.6bn). EBITDA margin dropped 450bps YoY but improved 2540bps QoQ to 40.4% (I-Sec: 30.2%). The company conducted 0.6mn COVID-19 tests which contributed ~41% to total sales in Q2FY21. Regular pathology business witnessed a volume decline of 23.1% in the number of samples but improved sequentially with easing of lockdown. Current performance has largely benefited from COVID-19 tests (~41% of revenue), sustainability of which remains uncertain. Coupled with concern on slower growth in the base business and recent run up in the stock has made valuations expensive, hence we downgrade to REDUCE.

- Strong growth led by COVID-19 tests: The company witnessed revenue growth of 31.8% YoY and 172% QoQ driven by growing volume. Regular pathology (ex-COVID tests) witnessed a YoY decline of 23.1% in number of samples, but QoQ it improved 126% with easing of lockdown. RT-PCR tests witnessed a 227% QoQ jump in volume and 104% rise in revenue despite declining realisations. Company also benefited from COVID-19 anti-body testing of 0.3mn samples in the quarter. Overall, COVID -19 tests generated Rs622mn of revenue in the quarter rising 166% QoQ and contributing ~41% of sales. Imaging business (Nueclear) also witnessed healthy recovery with 152% QoQ growth to Rs47mn (-45.3% YoY).

- EBITDA margin back to normal levels: Thyrocare reported EBITDA margin drop of 450bps YoY but grew 2540bps QoQ to 40.4%, better than our estimate of 30.2%. Sequential growth of revenue aided 1290bps improvement in gross margin. Despite rise in personnel costs and S,G&A expenses on absolute basis, as a percentage of sales the costs were sharply lower boosting margin. We believe S,G&A and personnel expenses would gradually increase with revenue as lockdown situation is easing restricting EBITDA margin around 40% for the next two years.

- Outlook: We raise our revenue and EBITDA estimates for FY21E by 27% and 35% to factor in COVID-19 tests and for FY22E-FY23E by 2-3% and 1-3% to factor in gradual recovery in non-COVID tests and lower cost structure. We expect non-COVID business to normalise in the coming months with pick up in the preventive care. Growth would be driven mainly by ~9% volume CAGR with stable realisation. Imaging business would continue to remain under pressure and we expect it to continue to negatively affect profitability.

- Valuations and risks: Concern on sustainability of COVID-19 revenue and slower growth in the base business coupled with recent run up in the stock has made valuations expensive, hence we downgrade to REDUCE from Hold with revised DCF-based target of Rs986/share, implying 33.2xFY23E earnings and 21.5x FY23E EBITDA. Key upside risks: faster recovery in preventive care business and incremental tie-ups with standalone labs for sample processing.

Shares of Thyrocare Technologies Ltd was last trading in BSE at Rs.1148.1 as compared to the previous close of Rs. 1138.15. The total number of shares traded during the day was 23305 in over 2489 trades.

The stock hit an intraday high of Rs. 1185.05 and intraday low of 1139.85. The net turnover during the day was Rs. 27218542.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com



Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019